AAAAAA

   
Results: 1-21 |
Results: 21
Liposome technology and the development of Myocet (TM) (liposomal doxorubicin citrate)
Authors: Swenson, CE Perkins, WR Roberts, P Janoff, AS
Citation: Ce. Swenson et al., Liposome technology and the development of Myocet (TM) (liposomal doxorubicin citrate), BREAST, 10, 2001, pp. 1-7
Untitled
Authors: Janoff, AS
Citation: As. Janoff, Untitled, J LIPOS RES, 11(1), 2001, pp. VII-VIII
The Seventh Liposome Research Days Conference - Napa Valley, California April 12-15, 2000 - Editorial
Authors: Janoff, AS
Citation: As. Janoff, The Seventh Liposome Research Days Conference - Napa Valley, California April 12-15, 2000 - Editorial, J LIPOS RES, 10(2-3), 2000, pp. VII-VIII
Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes
Authors: Li, X Cabral-Lilly, D Janoff, AS Perkins, WR
Citation: X. Li et al., Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes, J LIPOS RES, 10(1), 2000, pp. 15-27
Direct binding of lupus anticoagulant antibodies to nonbilayer phosphatidylethanolamine
Authors: Rauch, J Taraschi, TF Tannenbaum, M Janoff, AS
Citation: J. Rauch et al., Direct binding of lupus anticoagulant antibodies to nonbilayer phosphatidylethanolamine, J LIPOS RES, 10(1), 2000, pp. 29-41
Untitled
Authors: Janoff, AS
Citation: As. Janoff, Untitled, J LIPOS RES, 10(1), 2000, pp. VII-VIII
Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies
Authors: Subang, R Levine, JS Janoff, AS Davidson, SMK Taraschi, TF Koike, T Minchey, SR Whiteside, N Tannenbaum, M Rauch, J
Citation: R. Subang et al., Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies, J AUTOIMMUN, 15(1), 2000, pp. 21-32
Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds
Authors: Perkins, WR Ahmad, I Li, XG Hirsh, DJ Masters, GR Fecko, CJ Lee, JK Ali, S Nguyen, J Schupsky, J Herbert, C Janoff, AS Mayhew, E
Citation: Wr. Perkins et al., Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds, INT J PHARM, 200(1), 2000, pp. 27-39
Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine
Authors: Pushkareva, MY Wannberg, SL Janoff, AS Mayhew, E
Citation: My. Pushkareva et al., Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine, CANCER IMMU, 48(10), 2000, pp. 569-578
A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections
Authors: Adedoyin, A Swenson, CE Bolcsak, LE Hellmann, A Radowska, D Horwith, G Janoff, AS Branch, RA
Citation: A. Adedoyin et al., A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections, ANTIM AG CH, 44(10), 2000, pp. 2900-2902
Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion
Authors: Meers, P Ali, S Erukulla, R Janoff, AS
Citation: P. Meers et al., Novel inner monolayer fusion assays reveal differential monolayer mixing associated with cation-dependent membrane fusion, BBA-BIOMEMB, 1467(1), 2000, pp. 227-243
Elastase-activated liposomal delivery to nucleated cells (vol 1419, pg 111, 1999)
Authors: Pak, CC Erukulla, RK Ahl, PL Janoff, AS Meers, P
Citation: Cc. Pak et al., Elastase-activated liposomal delivery to nucleated cells (vol 1419, pg 111, 1999), BBA-BIOMEMB, 1463(1), 2000, pp. 195-195
Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice
Authors: Ahmad, I Masters, GR Schupsky, JJ Nguyen, J Ali, S Janoff, AS Mayhew, E
Citation: I. Ahmad et al., Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice, ONCOL RES, 11(6), 1999, pp. 273-280
Editorial
Authors: Janoff, AS
Citation: As. Janoff, Editorial, J LIPOS RES, 9(3), 1999, pp. VII-VIII
Untitled
Authors: Janoff, AS
Citation: As. Janoff, Untitled, J LIPOS RES, 9(1), 1999, pp. VII-VIII
Differential effects of free and liposome-associated 1-O-octadecyl-2-O-methylglycerophosphocholine on protein kinase C
Authors: Spiegel, S Olah, Z Cuvillier, O Edsall, LC Janoff, AS
Citation: S. Spiegel et al., Differential effects of free and liposome-associated 1-O-octadecyl-2-O-methylglycerophosphocholine on protein kinase C, FEBS LETTER, 454(1-2), 1999, pp. 137-141
Liposomal ET-18-OCH3 induces cytochrome c-mediated apoptosis independentlyof CD95 (APO-1/Fas) signaling
Authors: Cuvillier, O Mayhew, E Janoff, AS Spiegel, S
Citation: O. Cuvillier et al., Liposomal ET-18-OCH3 induces cytochrome c-mediated apoptosis independentlyof CD95 (APO-1/Fas) signaling, BLOOD, 94(10), 1999, pp. 3583-3592
Elastase activated liposomal delivery to nucleated cells
Authors: Pak, CC Erukulla, RK Ahl, PL Janoff, AS Meers, P
Citation: Cc. Pak et al., Elastase activated liposomal delivery to nucleated cells, BBA-BIOMEMB, 1419(2), 1999, pp. 111-126
Untitled
Authors: Janoff, AS
Citation: As. Janoff, Untitled, J LIPOS RES, 8(4), 1998, pp. V-VI
Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient
Authors: Li, XG Hirsh, DJ Cabral-Lilly, D Zirkel, A Gruner, SM Janoff, AS Perkins, WR
Citation: Xg. Li et al., Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient, BBA-BIOMEMB, 1415(1), 1998, pp. 23-40
The Liposome Company: Lipid-based pharmaceuticals in clinical development
Authors: Swenson, CE Freitag, J Janoff, AS
Citation: Ce. Swenson et al., The Liposome Company: Lipid-based pharmaceuticals in clinical development, MEDICAL APPLICATIONS OF LIPOSOMES, 1998, pp. 689-702
Risultati: 1-21 |